thermo outperform core
growth strong initi guid
total revenu y/i fx well ahead
estim organ growth vs estimate
beat broad-bas end-market product categori segment
well ahead forecast gross opmargin declin yoy expect
due pthn ddeal opm came close est adj ep
street est strong beat larg expect given peer result
recent bullish commentari better even bullish expect
scope breadth beat well clean natur non-oper item
tax rate share count net interest expens in-lin forecast
combin make one best qrt recent memori first look
page note detail result guidanc
environ ripe shine
initi organ sale guid in-lin expect
adj ep yoy ahead estimate said
view initi guid like conserv given first time mani year
tmo key end-market appear boom unison market
environ strength tmo diversifi global busi amplifi
competit tax worri fade believ share well-posit
narrow pe valuat gap lst peer moreov see upsid potenti
futur capit deploy given compani rapidli de-lever
net debt/ttm adj ebitda today vs end note announc
today first dividend increas sever year underscor confid
target reiter buy rate share
rais estim increas po
estimate sale y/i organ fx vs
prior adj ep y/i sale
organ yoy vs prior adj ep yoy vs
prior new po still dcf base w/ wacc due higher impli
market return termin growth rate improv metric
net dbt
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
thermo fisher scientif largest
consist analyt instrument lab
equip consum softwar servic
use throughout research drug manufactur
diagnost food consum product safeti
environment test
thermo fisher scientif largest life scienc
tool compani think recent acquisit
complementari technolog higher growth
on-going process improv initi
expand footprint emerg appli
market help grow revenu steadili
line even modestli better
overal tool market deliv low teen ep
compound-annual-growth-rate next sever year
life scienc solut sale segment sale
y/i organ fx flat vs estim y/i
organ fx segment benefit strong growth across
segment particularli bioproduct bioscienc busi opm
yoy strong product volum pull-through
foreign exchang partial off-set strateg invest
analyt instrument sale analyt instrument revenu
y/i organ fx vs
strength busi across segment opm flat yoy strong
product volum pull-through off-set strateg invest fx
specialti diagnost sale specialti diagnost revenu
y/i organ fx vs estim
y/i organ fx management report strong growth
season product like benefit high flu season good perform
clinic transplant diagnost busi opm yoy
contribut ppi busi system volum pull-through
off-set unfavor busi mix strateg invest
laboratori product servic lp sale laboratori product
servic lp revenu y/i organ fx
 vs estim y/i organ fx
 management note particularli good growth channel catalog busi
clinic trail busi neg affect recent quarter
discontinu larg phase clinic trial late opm
yoy favor volum pull-through accret impact
patheon acquisit off-set strateg invest unfavor
academ govern revenu grew high-singl digit y/i strong
demand mass spectrometri electron microscopi system growth
end-market mid-single-digit
diagnost healthcar sale grew high-singl digit driven
season busi flu strength biomark test full year growth
low-single-digit
industri appli growth end-market mid-singl digit
demand broad-bas particular strength
strength bioproduct clinic trial busi saw high-single-digit
growth end-market fy like ahead initi expect
given persist concern tough stack comp
north america sale sale grew high-singl digit msd
fy
europ sale sale grew mid-singl digit msd fy
asia pacif sale sale grew low-teen led china
sale sale growth high-teen apac growth
rest world sale sale grew low-teen y/i msd fy
revenu initi sale guid
yoy report fx tailwind organ
margin expect oper margin expans y/i
inclus margin dilut pthn acquisit
interest expens manag expect full year net interest expens
result pthn acquisit assum quarterli fed rate hike
tax rate manag expect adjust tax rate
level result recent pass us tax reform
capit deploy share buyback complet
second half also rais dividend total
dividend payment year usual compani note
capit deploy embed current guidanc excess
cash use repay debt
share count manag estim averag dilut share
vs due equiti offer financ pthn deal
capit expenditur manag expect net capit expenditur
approxim elev due time project
full-year impact patheon receiv approxim custom
fund toward capital-expenditure free cash flow expect
ep non-gaap ep guid yoy
inclus fx tailwind
po base dcf model assum wacc termin
growth rate impli multipl approxim ep estim given
size market leadership matur stabil compani consum
focus busi believ dcf appropri way valu
compani risk price object deal integr risk lower-than-expect
deal synergi slower growth emerg market price eros lower healthcar
util trend soft uptak new product competit weak fund
derik de bruin herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
becton dickinson compani
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
